SCHEMBL25263880

SCHEMBL25263880

Cn1cc(-c2cccc(C(=O)NCCC(=O)O)c2)cn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FYN P06241 1/20 0.52
▸ FGFR1 P11362 2/20 0.51
▸ FGFR3 P22607 2/20 0.51
▸ CTSV O60911 1/20 0.51
▸ CTSL P07711 1/20 0.51
▸ CTSB P07858 1/20 0.51
▸ CTSS P25774 1/20 0.51
▸ EGLN1 Q9GZT9 2/20 0.48
▸ KIT P10721 2/20 0.48
▸ CSF1R P07333 1/20 0.48
▸ IRAK4 Q9NWZ3 3/20 0.48
▸ IRAK1 P51617 2/20 0.48
▸ S1PR1 P21453 1/20 0.47
▸ NAMPT P43490 2/20 0.47
▸ ITGB3 P05106 1/20 0.46
▸ ITGA2B P08514 1/20 0.46
▸ CREBBP Q92793 1/20 0.46
▸ ROCK2 O75116 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC2 Q92769 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31362837 1.00 FYN (0.52) FYNFGFR1FGFR3CTSVCTSL
SCHEMBL11675554 0.80 PPARG (0.62) ITGB3ITGA2BHDAC1HDAC2PPARG
SCHEMBL31445330 0.80 CTSV (0.57) FYNFGFR1FGFR3CTSVCTSL
SCHEMBL29627308 0.79 KMO (0.54) FYNFGFR1FGFR3CTSVCTSL
SCHEMBL21816369 0.79 KMO (0.54) FYNFGFR1FGFR3CTSVCTSL
Hydrochloric Acid SCHEMBL29971276 0.78 KMO (0.53) FYNFGFR1FGFR3CTSVCTSL
SCHEMBL25814262 0.78 KIFC1 (0.50) FYNFGFR1FGFR3KITCSF1R
SCHEMBL30497153 0.76 KIFC1 (0.58) FYNS1PR1ITGB3ITGA2BHDAC1
SCHEMBL25297850 0.76 KIFC1 (0.58) FYNS1PR1ITGB3ITGA2BHDAC1
SCHEMBL25814238 0.76 KIFC1 (0.42) FYNFGFR1FGFR3CTSVCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250084074-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS MERCK PATENT GMBH (DE) 2025-03-13 — — US disclosed
EP-4463444-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS Merck Patent GmbH (DE) 2024-11-20 — — EP disclosed
WO-2023131690-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS MERCK PATENT GMBH (DE) 2023-07-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250084074-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS VHL, CDKN1A, CCNI FYN 2224/4885FGFR1 44/4885FGFR3 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback